

patient N°	1	2	3	4	5	6	7
sex	M	M	F	M	M	M	M
age (years)	41	58	64	74	71	45	55
N° of cycles at first eye exam	2	11	15	3	3	3	6
last eye exam	3	13	24	8	5	4	7
change in dosage	yes*	no	no	no	no	no	no
BCVA RE	1.0	1.0	1.0	0.7 – 0.9	0.8	1.0	1.0
LE	1.0	1.0	1.0	0.7 – 0.9	0.7	1.0	1.0
symptoms	circle centrally	blurred vision	no	blurred vision	floaters in LE, blurred vision	circle centrally	no
occurrence of symptoms after starting the therapy	1 week	1 week	-	1 week	1 month	1 week	-
fluctuations of symptoms	spontan. resolution	no	-	different spectacles needed	better after topical therapy	spontan. resolution	needs spectacles
OCT changes in the fovea	elongation of IZ	SRF	SRF	SRF	elongation of IZ in RE, SRF in LE	SRF	SRF
extrafoveal SRF	multiple bilateral	multiple bilateral	multiple bilateral	multiple bilateral	no	no	multiple bilateral
other ocular findings	-	-	-	incipient senile cataract ou	uveitis in LE; incipient cataract ou	-	dilatated conjunctival vessels in the RE

TABLE 1. Patient characteristics.

M = male, F = female; * adjusted dose = lower dose due to the cutaneous side effects;

RE = right eye; LE = left eye; BCVA = best corrected visual acuity; IZ = interdigitation zone; SRF = subretinal fluid; OCT = optical coherence tomography;